CytoMed Therapeutics Ltd
Company Profile
Business description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Contact
1 Commonwealth Lane
No. 08-22 One Commonwealth
Singapore149544
SGPT: +65 62507738
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
42
Stocks News & Analysis
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
stocks
Avoid this overvalued ASX lithium producer
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,975.10 | 30.50 | -0.34% |
| CAC 40 | 8,385.49 | 44.78 | 0.54% |
| DAX 40 | 24,740.36 | 153.22 | -0.62% |
| Dow JONES (US) | 51,848.90 | 182.06 | 0.35% |
| FTSE 100 | 10,461.63 | 32.78 | 0.31% |
| HKSE | 23,114.79 | 297.39 | -1.27% |
| NASDAQ | 25,476.64 | 110.40 | -0.43% |
| Nikkei 225 | 71,854.88 | 2,679.91 | 3.87% |
| NZX 50 Index | 13,494.22 | 93.56 | 0.70% |
| S&P 500 | 7,358.22 | 7.24 | -0.10% |
| S&P/ASX 200 | 8,775.10 | 25.50 | -0.29% |
| SSE Composite Index | 4,112.47 | 1.65 | 0.04% |